ACC HARD GELATIN

Main information

  • Trade name:
  • ACC HARD GELATIN
  • Pharmaceutical form:
  • Capsule
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • ACC HARD GELATIN
    Ireland
  • Language:
  • English

Other information

Status

  • Source:
  • HPRA - Health Products Regulatory Authority - Ireland
  • Authorization number:
  • PA0711/007/004
  • Authorization date:
  • 07-11-1996
  • Last update:
  • 14-10-2016

Summary of Product characteristics: dosage,interactions,side effects

PartII

SummaryofProductCharacteristics

1NAMEOFTHEMEDICINALPRODUCT

ACC200 mg Capsules.

2QUALITATIVEANDQUANTITATIVECOMPOSITION

Each capsulecontainsAcetylcysteine200 mg.

Forexcipients, see6.1.

3PHARMACEUTICALFORM

Hard Capsule.

White, opaque, hard gelatin capsule, filled with awhiteto offwhitepowder.

4CLINICALPARTICULARS

4.1TherapeuticIndications

ACCisindicated asan adjunctin thetreatmentofchronicbronchitisorotherrespiratory conditionsassociated with the

excessiveproduction ofviscousmucous.

4.2Posologyandmethodofadminstration

RouteofAdministration:

Oral.

RecommendedDosageSchedule

AcuteTherapy–Adults(over14years):

Theusualdoseisthreecapsules(3 x 200 mg)daily.

Children6-14years:

Theusualdoseistwo capsules(2x 200 mg)daily.

ChronicTherapy–Adults(over14years):

Theusualdaily doseistwo capsules(2 x 200 mg).

Mucoviscidosis–Childrenover6years:

Theusualdoseisthreecapsules(3 x 200 mg)daily.

In acuteexacerbationsatreatmentperiod of5-10 daysisusually adequatebutmay beextended ifnecessary.In chronic

bronchitisreliefofsymptomsmay benoticeableaftertreatmentfor1-2 monthsbuttreatmentmay beextended forup to

six months, e.g. duringwinterseason.When oralantibioticsordrugsarerequired they should beadministered 2 hours

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Issued 25/10/2005 CRN 2016088 page number: 1

4.3Contraindications

ACCiscontra-indicated in patientswho arehypersensitiveto acetylcysteineand in patientswith activepeptic

ulceration.

4.4Special warningsandspecialprecautionsforuse

Each sachetcontainstheequivalentof2.8 g ofsucrose.Thisshould betaken into accountwhen treating diabetic

patients.ACCshould begiven tonew-born infantsonly ifabsolutely necessary.

4.5Interactionwithothermedicinalproductsandotherformsofinteraction

ACCshouldnotbeadministered with oralantibioticswiththeexception ofamoxycillin, cefuroxime, doxycycline,

erythromycin and thiamphenicol.

Theconcomitantadministration ofACCwith oralantibioticsresultsin reduction oftheeffectivenessoftheantibiotics.

Antibioticsshould betaken atleast2hoursbeforeor2 hoursaftertaking ACC.

4.6Pregnancyandlactation

ACCCapsulesshould notbeadministered in pregnancyorduring lactation.

4.7Effectsonabilitytodriveandusemachines

Notapplicable.

4.8Undesirableeffects

Nausea, heartburn, vomiting, urticaria, headacheand tinnitushaveinfrequently been reported, buttheserarely

necessitatethewithdrawaloftreatment.Allergicskin reactions(itching and urticaria)and bronchospasm, especially in

asthmaticpatients, havebeen reported rarely in patientstaking oralacetylcysteine.High dosesofacetylcysteinegiven

intravenously havecaused anaphylactoid reactions.

4.9Overdose

Thereisno specificantidoteforacetylcysteineand treatmentissymptomatic.Itconsistsofposturaldrainage,

bronchialsuction and supportivetherapy isindicated.

5PHARMACOLOGICALPROPERTIES

5.1Pharmacodynamicproperties

Pharmacotherapeuticclassification (Group +ATCcode):

R05CB01

Respiratory System, Cough &Cold preparations, Mucolytics, Acetylcysteine

R05CB01

Sensory Organs, Ophthalmologicals, Otherophthalmologicals, Acetylcysteine

V03AB23

Various, Allothertherapeuticantidotes, Acetylcysteine

Acetylcysteinehasan intensemucolyticaction on mucoidand mucopurulentsecretionsdueto itsability to split

disulphidebondsin mucousglycoprotein. Thisproperty allowsitto beused asadjuvanttherapy in many clinical

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Issued 25/10/2005 CRN 2016088 page number: 2

tract.

5.2Pharmacokineticproperties

Notapplicable.

5.3Preclinical safetydata

Notapplicable.

6PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Mannitol

ColloidalAnhydrousSilica

StearicAcid

Shellexcipients:

Gelatin

TitaniumDioxide(E171)

6.2Incompatibilities

Notapplicable.

6.3ShelfLife

3 years.

6.4Special precautionsforstorage

Do notstoreabove25°C.Storein theoriginalpackage.

6.5Natureandcontentsofcontainer

ACC200 mg Capsulesarepacked in PVC/Aluminiumblisters.Thecapsulesareavailablein packsof6, 30 and 100

capsules.Notallpack sizesmay bemarketed.

6.6Instructionsforuseandhandling

No specificinstructionsrequired.

7MARKETINGAUTHORISATIONHOLDER

Rowex Ltd

Bantry

County Cork

8MARKETINGAUTHORISATIONNUMBER

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Issued 25/10/2005 CRN 2016088 page number: 3

9DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

Dateoffirstauthorisation: 7 th

November1996

Dateoflastrenewal: 7 th

November2001

10DATEOFREVISIONOFTHETEXT

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Issued 25/10/2005 CRN 2016088 page number: 4

4-12-2018

Signature Hardware recalls wall-mounted, folding teak shower seats

Signature Hardware recalls wall-mounted, folding teak shower seats

The aluminium hardware supporting the shower seat can corrode, posing fall and laceration hazards.

Health Canada

22-11-2018

Safety and efficacy of Monteban® G100 (narasin) for ducks for fattening

Safety and efficacy of Monteban® G100 (narasin) for ducks for fattening

Published on: Wed, 21 Nov 2018 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Monteban® G100 for ducks. Monteban® G100, containing narasin, is intended for the prevention of coccidiosis in ducks for fattening at a dose range of 60–70 mg/kg of complete feed. Narasin from Monteban® G100 is safe for ducks for fattening at a level of 70 mg/kg complete feed...

Europe - EFSA - European Food Safety Authority Publications

5-11-2018

Home Hardware Stores Ltd. Recalls Benchmark Step Ladder with Tray

Home Hardware Stores Ltd. Recalls Benchmark Step Ladder with Tray

The platform on the ladder does not lock securely in place posing a potential fall hazard.

Health Canada

1-11-2018

FDA warns patients and doctors about risk of inaccurate results from home-use device to monitor blood thinner warfarin

FDA warns patients and doctors about risk of inaccurate results from home-use device to monitor blood thinner warfarin

Roche Diagnostics issued voluntary recall of certain test strips used with CoaguChek meter devices; patients affected by the recall should seek alternative methods for testing.

FDA - U.S. Food and Drug Administration

1-11-2018

Publiekscampagne Ik Zorg van start

Publiekscampagne Ik Zorg van start

Vandaag gaven minister Hugo de Jonge, minister Bruno Bruins en staatssecretaris Paul Blokhuis het startsein voor de publiekscampagne Ik Zorg. Hiermee willen de sector Zorg en Welzijn en de overheid nieuwe werknemers aantrekken. Dat is hard nodig, om ook in de toekomst iedereen goede zorg te kunnen blijven bieden. Als we nu niks doen, hebben we in 2022 een tekort van 125.000 mensen.

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

27-9-2018

Staatssecretaris Blokhuis: “Bij aanpak personen met verward gedrag is de regio aan zet”

Staatssecretaris Blokhuis: “Bij aanpak personen met verward gedrag is de regio aan zet”

Met het beëindigen van het Schakelteam Personen met Verward Gedrag per 1 oktober gaat de aanpak van personen met verward gedrag een nieuwe fase tegemoet. In zijn eindrapport geeft het Schakelteam een inventarisatie van de huidige stand van zaken en worden aanbevelingen gedaan voor de toekomst. Het Schakelteam constateert dat er veel is gebeurd in de afgelopen twee jaar. Zo is er een landelijk dekkende structuur gerealiseerd waarin hard wordt gewerkt aan goede zorg en ondersteuning van mensen met verward ...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

11-9-2018

Novel foods: a risk profile for the house cricket (Acheta domesticus)

Novel foods: a risk profile for the house cricket (Acheta domesticus)

Published on: Tue, 28 Aug 2018 00:00:00 +0200 Novel foods could represent a sustainable alternative to traditional farming and conventional foodstuffs. Starting in 2018, Regulation (EU) 2283/2015 entered into force, laying down provisions for the approval of novel foods in Europe, including insects. This Approved Regulation establishes the requirements that enable Food Business Operators to bring new foods into the EU market, while ensuring high levels of food safety for European consumers. The present ...

Europe - EFSA - European Food Safety Authority Publications

7-9-2018

Orphan designation:  Recombinant human beta-glucuronidase (vestronidase alfa),  for the: Treatment of mucopolysaccharidosis type VII (Sly syndrome)

Orphan designation: Recombinant human beta-glucuronidase (vestronidase alfa), for the: Treatment of mucopolysaccharidosis type VII (Sly syndrome)

On 21 March 2012, orphan designation (EU/3/12/973) was granted by the European Commission to NDA Regulatory Science Ltd, United Kingdom, for recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type VII (Sly syndrome).

Europe - EMA - European Medicines Agency

30-8-2018

Great Canadian Dollar Store recalls Lobster Plush Toys

Great Canadian Dollar Store recalls Lobster Plush Toys

Health Canada's sampling and evaluation program has determined that these plush toys do not meet the Canadian safety requirements for toys. The hard plastic eyes on these plush toys can detach, posing a choking hazard to young children.

Health Canada

29-8-2018

Protocol for the scientific opinion on the Tolerable Upper Intake Level of dietary sugars

Protocol for the scientific opinion on the Tolerable Upper Intake Level of dietary sugars

Published on: Fri, 10 Aug 2018 00:00:00 +0200 In June 2016, EFSA received a mandate from the national food competent authorities of five European countries (Denmark, Finland, Iceland, Norway and Sweden) to provide a dietary reference value (DRV) for sugars, with particular attention to added sugars. A draft protocol was developed with the aim of defining as much as possible beforehand the strategy that will be applied for collecting data, appraising the relevant evidence, and analysing and integrating t...

Europe - EFSA - European Food Safety Authority Publications

28-8-2018

Consumer Alert - Undeclared Sulfites in “Lily Bulb”

Consumer Alert - Undeclared Sulfites in “Lily Bulb”

New York State Agriculture Commissioner Richard A. Ball today alerted consumers that the “Lily Bulb” product (photo attached) distributed by Allied Imports Inc. of 267 52nd Street, Brooklyn, NY 11220 was found to contain sulfites, which are not declared on the product label. People who have severe sensitivity to sulfites may run the risk of serious or life-threatening reactions if they consume this product. No illnesses have been reported to date to this Department in connection with this product.

FDA - U.S. Food and Drug Administration

14-8-2018

The Uttermost Company recalls Various Types of Mirrors, Art and Wall Décor sold with Adjustable J-Hook Hanging Hardware

The Uttermost Company recalls Various Types of Mirrors, Art and Wall Décor sold with Adjustable J-Hook Hanging Hardware

The hanging hardware can break, causing mirrors and wall décor to fall from walls, posing an injury hazard to bystanders.

Health Canada

3-8-2018

Scientific guideline:  Vismodegib hard capsule 150 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Vismodegib hard capsule 150 mg product-specific bioequivalence guidance, adopted

Vismodegib hard capsule 150 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

17-7-2018

Blokhuis kondigt grootschalige extra vaccinatie aan: Ruim half miljoen kinderen krijgen oproep

Blokhuis kondigt grootschalige extra vaccinatie aan: Ruim half miljoen kinderen krijgen oproep

Volgend jaar worden zo’n 650.000 kinderen extra opgeroepen om zich te laten inenten tegen de zeer ernstige infectieziekte meningokokken. Het gaat om kinderen die zijn geboren na 1 januari 2001 en voor mei 2004. Dat laat staatssecretaris Paul Blokhuis (VWS) weten in een brief aan de Tweede Kamer. Reden voor deze maatregel is dat in de afgelopen jaren een stijging te zien is van het aantal mensen dat de infectie meningokokken type W oploopt. Met deze extra vaccinatieronde moet die groei worden ingedamd. He...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

26-6-2018

Home Hardware Stores Ltd. recalls Home Flexible Multi-Purpose Lighter

Home Hardware Stores Ltd. recalls Home Flexible Multi-Purpose Lighter

Health Canada's sampling and evaluation program has determined that these lighters do not meet the Lighters Regulations in Canada and may pose a fire or burn hazard. Specifically the lighters:

Health Canada

12-6-2018

Blokhuis: harde feiten gif in sigaretten zeer zorgelijk

Blokhuis: harde feiten gif in sigaretten zeer zorgelijk

Teer, nicotine en koolmonoxide gehalten in sigaretten die gemeten worden volgens de Canadian Intense (CI) methode zijn minimaal twee keer zo hoog als de gehalten gemeten met de wettelijke voorgeschreven ISO methode waarmee de EU en dus ook Nederland werkt. In sommige gevallen liggen de gehaltes zelfs tot meer dan 20 keer hoger. Dat blijkt uit onderzoek van het RIVM, dat 100 sigaretten onder de loep nam. Staatssecretaris Paul Blokhuis (VWS) heeft als opdrachtgever het onderzoek vandaag in ontvangst genome...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

25-4-2018

Magnetic Resonance-guided Laser Interstitial Thermal Therapy (MRgLITT) Devices: Letter to Health Care Providers - Risk of Tissue Overheating Due to Inaccurate Magnetic Resonance Thermometry

Magnetic Resonance-guided Laser Interstitial Thermal Therapy (MRgLITT) Devices: Letter to Health Care Providers - Risk of Tissue Overheating Due to Inaccurate Magnetic Resonance Thermometry

FDA is currently evaluating data which suggests that potentially inaccurate MR thermometry information can be displayed during treatment. Posted 04/25/2018

FDA - U.S. Food and Drug Administration

6-4-2018

"Organic Traditions Shatavari Powder" sold at Choices Markets Yaletown in Vancouver, B.C., contaminated with Salmonella

"Organic Traditions Shatavari Powder" sold at Choices Markets Yaletown in Vancouver, B.C., contaminated with Salmonella

Health Canada is advising Canadians that one lot of “Organic Traditions Shatavari Powder” is being voluntarily recalled by Advantage Health Matters Inc. Company testing found Salmonella bacteria contamination, which may pose serious health risks. According to Advantage Health Matters Inc., 13 units from the affected lot were distributed. Of the 13 units, only 2 packages, sold at Choices Markets Yaletown (1202 Richards Street) in Vancouver, B.C., have not been recovered.

Health Canada

22-12-2009

Warning against the potency-enhancing product Rock Hard Weekend

Warning against the potency-enhancing product Rock Hard Weekend

The Danish Medicines Agency strongly warns against using the potency-enhancing product Rock Hard Weekend after the FDA (U.S. Food and Drug Administration) has notified the Danish Medicines Agency that Rock Hard Weekend contains an undeclared active substance and that the product has been exported from the USA to Denmark.

Danish Medicines Agency

2-11-2018

.@US_FDA  issues a class I recall: Roche Diagnostics recalls CoaguChek  XS PT Test  Strips due to inaccurate INR test results. Find out more:  https://go.usa.gov/xPVER  #FDA #MedicalDevicepic.twitter.com/EYmVZHrUZc

.@US_FDA issues a class I recall: Roche Diagnostics recalls CoaguChek XS PT Test Strips due to inaccurate INR test results. Find out more: https://go.usa.gov/xPVER  #FDA #MedicalDevicepic.twitter.com/EYmVZHrUZc

. @US_FDA issues a class I recall: Roche Diagnostics recalls CoaguChek XS PT Test Strips due to inaccurate INR test results. Find out more: https://go.usa.gov/xPVER  #FDA #MedicalDevice pic.twitter.com/EYmVZHrUZc

FDA - U.S. Food and Drug Administration

21-10-2018

We know that cancer is harder to find in women with dense breasts – some women may need other imaging tests. Breast density reporting is already required in some states. Expanding this nationwide will empower patients and providers to make more informed h

We know that cancer is harder to find in women with dense breasts – some women may need other imaging tests. Breast density reporting is already required in some states. Expanding this nationwide will empower patients and providers to make more informed h

We know that cancer is harder to find in women with dense breasts – some women may need other imaging tests. Breast density reporting is already required in some states. Expanding this nationwide will empower patients and providers to make more informed health decisions.

FDA - U.S. Food and Drug Administration

11-10-2018

October is #SIDSAwarenessMonth.  Smoking during pregnancy can lead to complications, premature delivery, low birth weight, stillbirth, and SIDS. Make sure your baby is #safetosleep at  https://women.smokefree.gov/  via @FDATobaccopic.twitter.com/i37QX61Bb

October is #SIDSAwarenessMonth. Smoking during pregnancy can lead to complications, premature delivery, low birth weight, stillbirth, and SIDS. Make sure your baby is #safetosleep at https://women.smokefree.gov/  via @FDATobaccopic.twitter.com/i37QX61Bb

October is #SIDSAwarenessMonth. Smoking during pregnancy can lead to complications, premature delivery, low birth weight, stillbirth, and SIDS. Make sure your baby is #safetosleep at https://women.smokefree.gov/  via @FDATobacco pic.twitter.com/i37QX61Bb7

FDA - U.S. Food and Drug Administration

27-8-2018

Strimvelis (Orchard Therapeutics (Netherlands) B.V.)

Strimvelis (Orchard Therapeutics (Netherlands) B.V.)

Strimvelis (Active substance: autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5703 of Mon, 27 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3854/T/14

Europe -DG Health and Food Safety

6-8-2018

Scientific guideline:  Draft guideline on the use of minimal residual disease as a clinical endpoint in multiple myeloma studies, draft: consultation open

Scientific guideline: Draft guideline on the use of minimal residual disease as a clinical endpoint in multiple myeloma studies, draft: consultation open

The guideline aims to address the use of undetectable minimal residual disease (MRD) as an intermediate efficacy endpoint in controlled randomised clinical studies in patients with multiple myeloma (MM), adequately designed to demonstrate efficacy by relevant hard endpoints. MRD as an endpoint in this context would allow earlier approval of new drugs pending final confirmatory data.

Europe - EMA - European Medicines Agency

2-8-2018

EU/3/16/1660 (Orchard Therapeutics Ltd)

EU/3/16/1660 (Orchard Therapeutics Ltd)

EU/3/16/1660 (Active substance: Autologous CD34+ cells transduced with lentiviral vector encoding the human beta globin gene) - Transfer of orphan designation - Commission Decision (2018)5288 of Thu, 02 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/024/16/T/02

Europe -DG Health and Food Safety

2-8-2018

EU/3/07/446 (Orchard Therapeutics Ltd)

EU/3/07/446 (Orchard Therapeutics Ltd)

EU/3/07/446 (Active substance: Autologous CD34+ cells transfected with lentiviral vector containing the human arylsulfatase A cDNA) - Transfer of orphan designation - Commission Decision (2018)5287 of Thu, 02 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/102/06/T/02

Europe -DG Health and Food Safety

27-7-2018

EU/3/12/998 (Orchard Therapeutics Ltd)

EU/3/12/998 (Orchard Therapeutics Ltd)

EU/3/12/998 (Active substance: Autologous CD34+ cells transfected with lentiviral vector containing the Wiskott-Aldrich syndrome protein gene) - Transfer of orphan designation - Commission Decision (2018)5062 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/014/12/T/02

Europe -DG Health and Food Safety